ABSTRACT
Drug therapy for obesity has experienced a very checkered past. Starting in the 1930s, over 10 drugs with various mechanisms of action have been approved in the United States for weight loss including three for long-term therapy, yet in 2011 only one drug remains on the market [1]. Nonprescription weight loss medications such as phenylpropanolamine hydrochloride (PPA) have had a similar fate.
